Skip to content

Single Photon Emission Computed Tomography (SPECT) Lymph Node Mapping

SPECT Lymph Node Mapping to Define Nodal Clinical Target Volume in Patients With Prostate Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00608920
Acronym
SPECT
Enrollment
15
Registered
2008-02-06
Start date
2007-03-31
Completion date
2009-04-30
Last updated
2013-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenocarcinoma of the Prostate

Keywords

SPECT

Brief summary

The purpose of this study is to determine if the planning of radiation treatment of prostate cancer patient can be made more precise by comparing currently planning techniques to an imaging technique called SPECT.

Detailed description

Single photon emission computed tomography (SPECT) uses radioactive tracers and a scanner to record data that a computer constructs into two- or three-dimensional images. A small amount of a radioactive drug is injected into the body and a scanner is used to make detailed images of areas inside the body where the radioactive material is taken up by the cells. Using a gamma camera (a special kind of scanner), we can create a better picture of the lymph node region. We will compare these pictures to images from your CT scan, to help plan your therapy. The research in this study involves seeing if it is feasible to use SPECT scanning procedures for the purpose of planning your radiation treatment. We hope that doing so will allow us to more accurately and precisely plan radiation treatment to potential sites of cancer, and avoid delivering too much radiation to normal

Interventions

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with biopsy proven adenocarcinoma of the prostate * Patients with at least one of the following high risk clinical features at the time of presentation: * Extra-prostatic extension (on palpation or radiographic imaging) * PSA ≥ 20 * Gleason Score ≥ 8 * Patients scheduled to receive prostatic and pelvic IMRT with ACCULOC® target localization * Age \> 18 years * ECOG Performance Status ≤ 2 * Willing and able to sign informed consent document.-

Exclusion criteria

* History of radical prostatectomy * History of prior pelvic radiation-

Design outcomes

Primary

MeasureTime frameDescription
Determine the feasibility of using SPECT-LMCompletion of enrollment of all patientsSafety: The study will be feasible if no more than 80% of patients experience the following complications: infection requiring hospitalization or IV antibiotics, urinary retention requiring placement of a Foley catheter, moderate or severe allergic reaction to Tc99. Efficacy: The study will be feasible if at least 80% of patients have at least one identifiable lymph node on SPECT-LM.

Secondary

MeasureTime frameDescription
Evaluate the extent to which current target delineation guidelines include actual lymphatic channels visualized on SPECT-LM in the study population.Completion of enrollment of all patients1. Greatest radial distance of lymphatic channel volume from vessel wall contour 2. Fraction of lymphatic channel volume, normal tissue volume, and critical structure volumes included in radial expansions from vessel wall

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026